Literature DB >> 10424338

Clear cell chondrosarcoma of the pelvis in a skeletally immature patient.

T Ishida1, M Yamamoto, T Goto, H Kawano, A Yamamoto, R Machinami.   

Abstract

We report on a case of clear cell chondrosarcoma (CCCS) of the left iliac bone in a 12-year-old skeletally immature boy. Radiographic examination revealed an aggressive osteolytic lesion with areas of mineralization. Fluid-fluid levels were seen on T2-weighted MR images. Laboratory data showed slight elevation of serum alkaline phosphatase. The biopsy specimen showed histological features of CCCS with some resemblance to osteosarcoma, such as prominent irregular osteoid formation among clear tumor cells. Surgical treatment was accomplished without pre- or post-operative chemotherapy. Because of the patient's age, elevated serum alkaline phosphatase, and histopathology with prominent osteoid production, this case could be confused with osteosarcoma. Although CCCS is an extremely rare bone tumor in children, it is important to be aware that it may arise in a skeletally immature patient. CCCS, unlike osteosarcoma, is not treated with neo-adjuvant chemotherapy.

Entities:  

Mesh:

Year:  1999        PMID: 10424338     DOI: 10.1007/s002560050519

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  3 in total

1.  Fluid-fluid levels in bone neoplasms: variation of T1-weighted signal intensity of the superior to inferior layers--diagnostic significance on magnetic resonance imaging.

Authors:  Faisal Alyas; Asif Saifuddin
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

2.  An unusual case of clear cell chondrosarcoma with very late recurrence and lung metastases, 29 years after primary surgery.

Authors:  Minna Laitinen; Jyrki Nieminen; Toni-Karri Pakarinen
Journal:  Case Rep Orthop       Date:  2014-07-20

3.  Clear cell chondrosarcoma is an underestimated tumor: Report of 7 cases and meta-analysis of the literature.

Authors:  Alexander Klein; Felix Tauscher; Christof Birkenmaier; Andrea Baur-Melnyk; Thomas Knösel; Volkmar Jansson; Hans Roland Dürr
Journal:  J Bone Oncol       Date:  2019-10-31       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.